Previous 10 | Next 10 |
home / stock / podd / podd articles
Insulet (NASDAQ:PODD) has outperformed the market over the past 15 years by 12.41% on an annualized basis producing an average annual return of 25....
Insulet (NASDAQ:PODD) has outperformed the market over the past 15 years by 12.24% on an annualized basis producing an average annual return of 24....
These large-cap stocks were the best performers in the last week. Are they in your portfolio? MicroStrategy Incorporated (NASDAQ:MSTR) shares inc...
Insulet Corporation (NASDAQ: PODD) reported GAAP earnings per share of 73 cents for first-quarter 2024, which significantly improved from the year-...
U.S. stocks were slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Shares of Surgery Partners, Inc. (NASDAQ: SGRY) fe...
U.S. stocks could see a pause on Friday as traders take a breather following the impressive rally on Thursday, sparked by Nvidia Corp.’s (...
Investors pinned hopes on Nvidia Corp.’s (NASDAQ:NVDA) earnings to reinvigorate market momentum, and the AI leader delivered an impressive ...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
The markets exhibited a mixed trend Monday, with technology heavyweights experienced a slight downturn as investors adopt a cautious approach ahead...
News, Short Squeeze, Breakout and More Instantly...
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2024 on August 8, 2024 after the close of the financial...
Largest, longest, and most racially diverse study of automated insulin delivery (AID) conducted in people with type 2 diabetes to date Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® bra...
Following a successful limited market release, the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now fully available with Dexcom G6 and Abbott FreeStyle Libre 2 Plus in these countries Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tub...